Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Presidential risk assessment

This article was originally published in The Gray Sheet

Executive Summary

Office of Management and Budget official John Graham endeavors to bring in outside expertise in risk assessment as a part of the administration's performance-based management system. Graham, OMB's administrator of the Office of Information and Regulatory Affairs, "is a leading expert in the nation on decision sciences in risk assessment and cost benefit analysis," according to OMB's Paul Noe at the Washington Legal Foundation, June 4. OIRA "is traditionally an office dominated by economists and [Graham] is trying to expand and deepen our expertise." Risk assessment has taken on more emphasis since the appointment of Acting FDA Director Lester Crawford, who views his role to be "risk manager" (1"The Gray Sheet" April 22, 2002, p. 5)...

You may also be interested in...

Hatch Takes Aim At Kennedy’s Commissioner Criteria, Supports Crawford

Ties to an FDA-regulated industry should not preclude a candidate's nomination to the agency's top position, Sen. Orrin Hatch (R-Utah) asserted April 16 at the Food & Drug Law Institute Educational Conference in Washington, D.C

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts